Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.2857.

A number of equities research analysts recently weighed in on the stock. Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals in a report on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st.

Enanta Pharmaceuticals Trading Up 1.3%

NASDAQ ENTA opened at $13.14 on Friday. The company has a market cap of $381.32 million, a P/E ratio of -4.11 and a beta of 0.99. The company has a fifty day simple moving average of $13.43 and a 200 day simple moving average of $12.73. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. The firm had revenue of $18.62 million for the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. Sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ENTA. Janus Henderson Group PLC grew its stake in shares of Enanta Pharmaceuticals by 91.6% in the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after acquiring an additional 1,782,745 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after purchasing an additional 650,000 shares in the last quarter. Krensavage Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after purchasing an additional 651,946 shares in the last quarter. Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Enanta Pharmaceuticals by 0.8% during the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.